Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice

Laboratory Investigation

Volumn 83, Issue 1, 2003, Pages 75-85

  Yanagawa, Bobby ^a   Spiller, O Brad ^b   Choy, Jonathan ^a   Luo, Honglin ^a   Cheung, Paul ^a   Zhang, Huifang M ^a   Goodfellow, Ian G ^c   Evans, David J ^c   Suarez, Agripina ^a   Yang, Decheng ^a   McManus, Bruce M ^a  

^a ST PAUL S HOSPITAL   (Canada)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DECAY ACCELERATING FACTOR; EOSIN; FC RECEPTOR; HEMATOXYLIN; HYBRID PROTEIN; IMMUNOGLOBULIN G1; RECOMBINANT CYTOKINE; RECOMBINANT SOLUBLE HUMAN DECAY ACCELERATING FACTOR; UNCLASSIFIED DRUG; VIRUS RNA;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CLINICAL FEATURE; COMPLEMENT INHIBITION; CONTROLLED STUDY; COXSACKIE VIRUS B3; HEART; HEART DILATATION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IN SITU HYBRIDIZATION; KIDNEY; LIVER; MOUSE; MYOCARDITIS; MYOPATHY; NONHUMAN; PANCREAS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SCORING SYSTEM; SPLEEN; STAINING; STATISTICAL SIGNIFICANCE; STRAIN IDENTIFICATION; VIRUS INFECTION; VIRUS LOAD; VIRUS MYOCARDITIS;

EID: 0037241984     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000049349.56211.09     Document Type: Article

References (54)

1. Anderson DR, Wilson JE, Carthy CM, Yang D, Kandolf R, and McManus BM (1996). Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. J Virol 70:4632-4645.
2. Barrington R, Zhang M, Fischer M, and Carroll MC (2001). The role of complement in inflammation and adaptive immunity. Immunol Rev 180:5-15.
3. Batra AS and Lewis AB (2001). Acute myocarditis. Curr Opin Pediatr 13:234-239.
4. Bauer S, Gottesman G, Sirota L, Litmanovitz I, Ashkenazi S, and Levi I (2002). Severe Coxsackie virus B infection in preterm newborns treated with pleconaril. Eur J Pediatr 161:491-493.
5. Bergelson JM, Krithivas A, Celi L, Droguett G, Horwitz MS, Wickham T, Crowell RL, and Finberg RW (1998). The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 72:415-419.
6. Bergelson JM, Modlin JF, Wieland-Alter W, Cunningham JA, Crowell RL, and Finberg RW (1997). Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors. J Infect Dis 175:697-700.
7. Bergelson JM, Mohanty JG, Crowell RL, St. John NF, Lublin DM, and Finberg RW (1995). Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J Virol 69:1903-1906.
8. Carson SD and Chapman NM (2001). Coxsackievirus and adenovirus receptor (CAR) binds immunoglobulins. Biochemistry 40:14324-14329.
9. Carthy CM, Granville DJ, Watson KA, Anderson DR, Wilson JE, Yang D, Hunt DW, and McManus BM (1998). Caspase activation and specific cleavage of substrates after coxsackievirus B3-induced cytopathic effect in HeLa cells. J Virol 72:7669-7675.
10. Chow LH, Beisel KW, and McManus BM (1992). Enteroviral infection of mice with severe combined immunodeficiency: Evidence for direct viral pathogenesis of myocardial injury. Lab Invest 66:24-31.
11. Chow LH, Gauntt CJ, and McManus BM (1991). Differential effects of myocarditic variants of coxsackievirus B3 in inbred mice: A pathologic characterization of heart tissue damage. Lab Invest 64:55-64.
12. Chow LH, Gauntt CJ, Ye YL, and McManus BM (1988). Early cellular infiltrates in coxsackievirus B3 murine myocarditis. In: Schultheib HP, editor. New concepts in viral heart disease. Munich: Springer-Verlag, 205-214.
13. Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, and Bergelson JM (2001). The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci USA 98:15191-15196.
14. Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, Baker AL, Perez-Atayde AR, and Newburger JW (1994). Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89:252-257.
15. Fohlman J, Pauksen K, Morein B, Bjare U, Ilback NG, and Friman G (1993). High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis. Scand J Infect Dis Suppl 88:103-108.
16. Geller TJ and Condie D (1995). A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin. J Neurol Sci 129:131-133.
17. Grun JB, Schultz M, Finkelstein SD, Crowell RL, and Landau BJ (1988). Pathogenesis of acute myocardial necrosis in inbred mice infected with coxsackievirus B3. Microb Pathog 4:417-430.
18. Harris CL, Rushmere NK, and Morgan BP (1999). Molecular and functional analysis of mouse decay accelerating factor (CD55). Biochem J 341:821-829.
19. Harris CL, Spiller OB, and Morgan BP (2000). Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology 100:462-470.
20. Harris CL, Williams AS, Linton SM, and Morgan BP (2002). Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol 129:198-207.
21. Isacsohn M, Eidelman Al, Kaplan M, Goren A, Rudensky B, Handsher R, and Barak Y (1994). Neonatal coxsackievirus group B infections: Experience of a single department of neonatology. Isr J Med Sci 30:371-374.
22. Ito M, Kodama M, Masuko M, Yamaura M, Fuse K, Uesugi Y, Hirono S, Okura Y, Kato K, Hotta Y, Honda T, Kuwano R, and Aizawa Y (2000). Expression of coxsackievirus and adenovirus receptor in hearts of rats with experimental autoimmune myocarditis. Circ Res 86:275-280.
23. Kaplan MH, Klein SW, McPhee J, and Harper RG (1983). Group B coxsackievirus infections in infants younger than three months of age: A serious childhood illness. Rev Infect Dis 5:1019-1032.
24. Krah DL and Crowell RL (1982). A solid-phase assay of solubilized HeLa cell membrane receptors for binding group B coxsackieviruses and polioviruses. Virology 118:148-156.
25. Kunin CM (1964). Cellular susceptibility to enteroviruses. Bact Rev 28:382-390.
26. Landau BJ, Whittier PS, Finkelstein SD, Alstein B, Grun JB, Schultz M, and Crowell RL (1990). Induction of heterotypic virus resistance in adult inbred mice immunized with a variant of Coxsackievirus B3. Microb Pathog 8:289-298.
27. Liu P, Aitken K, Kong YY, Opavsky MA, Martino T, Dawood F, Wen WH, Kozieradzki I, Bachmaier K, Straus D, Mak TW, and Penninger JM (2000). The tyrosine kinase p561ck is essential in coxsackievirus B3-mediated heart disease. Nat Med 6:429-434.
28. Liu PP and Opavsky MA (2000). Viral myocarditis: Receptors that bridge the cardiovascular with the immune system? Circ Res 86:253-254.
29. Lo KM, Sudo Y, Chen J, Li Y, Lan Y, Kong SM, Chen L, An Q, and Gillies SD (1998). High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng 11:495-500.
30. Maisch B, Hufnagel G, Schonian U, and Hengstenberg C (1995). The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Eur Heart J 16 (Suppl O):173-175.
31. Martino TA, Petric M, Brown M, Aitken K, Gauntt CJ, Richardson CD, Chow LH, and Liu PP (1998). Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor. Virology 244:302-314.
32. Martino TA, Petric M, Weingartl H, Bergelson JM, Opavsky MA, Richardson CD, Modlin JF, Finberg RW, Kain KC, Willis N, Gauntt CJ, and Liu PP (2000). The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B and by swine vesicular disease virus. Virology 271:99-108.
33. Mason JW, JB OC, Herskowitz A, Rose NR, McManus BM, Billingham ME, and Moon TE (1995). A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333:269-275.
34. McManus BM, Chow LH, Wilson JE, Anderson DR, Gulizia JM, Gauntt CJ, Klingel KE, Beisel KW, and Kandolf R (1993). Direct myocardial injury by enterovirus: A central role in the evolution of murine myocarditis. Clin Immunol Immunopathol 68:159-169.
35. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, and Austen KF (1982). Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 129:184-189.
36. Nicholson-Weller A and Wang CE (1994). Structure and function of decay accelerating factor CD55. J Lab Clin Med 123:485-491.
37. Pasch A, Kupper JH, Wolde A, Kandolf R, and Selinka HC (1999). Comparative analysis of virus-host cell interactions of haemagglutinating and non-haemagglutinating strains of coxsackievirus B3. J Gen Virol 80:3153-3158.
38. Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, and Marks JD (2001). Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods 251:123-135.
39. Reagan KJ, Goldberg B, and Crowell RL (1984). Altered receptor specificity of coxsackievirus B3 after growth in rhabdomyosarcoma cells. J Virol 49:635-640.
40. Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht HJ, Johnson JE, Kamer G, Luo M, Mosser AG, et al (1985). Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317:145-153.
41. Rotbart HA and Webster AD (2001). Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 32:228-235.
42. Schmidtke M, Selinka HC, Heim A, Jahn B, Tonew M, Kandolf R, Stelzner A, and Zell R (2000). Attachment of coxsackievirus B3 variants to various cell lines: Mapping of phenotypic differences to capsid protein VP1. Virology 275:77-88.
43. Shafren DR, Bates RC, Agrez MV, Herd RL, Burns GF, and Barry RD (1995). Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J Virol 69:3873-3877.
44. Shafren DR, Williams DT, and Barry RD (1997). A decayaccelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells. J Virol 71:9844-9848.
45. Shieh JT and Bergelson JM (2002). Interaction with decayaccelerating factor facilitates coxsackievirus B infection of polarized epithelial cells. J Virol 76:9474-9480.
46. Spiller OB, Goodfellow IG, Evans DJ, Almond JW, and Morgan BP (2000). Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF. J Infect Dis 181:340-343.
47. Spiller OB, Goodfellow IG, Evans DJ, Hinchliffe SJ, and Morgan BP (2002). Coxsackie B viruses that use human DAF as a receptor infect pig cells via pig CAR and do not use pig DAF. J Gen Virol 83:45-52.
48. Takada H, Kishimoto C, and Hiraoka Y (1995). Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model: Antiviral and anti-inflammatory effects. Circulation 92:1604-1611.
49. Tedeschi A, Airaghi L, Giannini S, Ciceri L, and Massari FM (2002). High-dose intravenous immunoglobulin in the treatment of acute myocarditis: A case report and review of the literature. J Intern Med 251:169-173.
50. Tracy S, Chapman NM, and Mahy BWJ (1997). The coxsackie B viruses, 1st ed. Berlin: Springer-Verlag.
51. Valduss D, Murray DL, Karna P, Lapour K, and Dyke J (1993). Use of intravenous immunoglobulin in twin neonates with disseminated coxsackie B1 infection. Clin Pediatr (Phila) 32:561-563.
52. Walport MJ (2001). Complement: First of two parts. N Engl J Med 344:1058-1066.
53. Wang A, Cheung PK, Zhang H, Carthy CM, Bohunek L, Wilson JE, McManus BM, and Yang D (2001). Specific inhibition of coxsackievirus B3 translation and replication by phosphorothioate antisense oligodeoxynucleotides. Antimicrob Agents Chemother 45:1043-1052.
54. Woodruff JF (1980). Viral myocarditis: A review. Am J Pathol 101:425-484.